[bioundgrd] FW: Roivant Sciences Info Session (Today 9/29, Room 32-144)

[Joshua Stone]

Begin forwarded message:





[cid:image001.png at 01D21A5B.B33644B0]







ROIVANT SCIENCES COMPANY PRESENTATION

Thursday, September 29, 2016 | 7:30 - 9:00 p.m.
Location 32-144
Dinner from Flour will be served

Hello from Roivant’s MIT recruiting team!

We invite you to join Mayukh Sukhatme ’97, SVP Business Development, to learn about Roivant Sciences’ disruptive approach to pharmaceutical drug development. He will discuss Roivant’s founding insight, its extraordinary growth and accomplishments, and its exciting future trajectory, as well as your potential impact in a role at Roivant.

At Roivant, we embrace the joint effort of scientific, financial, and technical minds to assist in the evaluation, acquisition, and development of target pharmaceutical assets. We welcome exceptional full-time candidates from all majors with demonstrated intellectual curiosity and achievement—a life sciences background is by no means required. Depending on your interests, your role could involve asset diligence and evaluation, product development, corporate strategy, business operations, finance, or a combination of the above. You will work side-by-side with experienced professionals and senior management to drive critical investment, development, and operational decisions, and to execute on those initiatives.

A number of Roivant’s recent MIT alums will also be in attendance to share their experiences at the company.


WHO IS ROIVANT SCIENCES?

Roivant Sciences is a unique biopharmaceutical company dedicated to realizing the full value of promising drug candidates by systematically reducing the time, cost, and risk of delivering new drugs to patients. At Roivant, we aim to identify under-resourced or deprioritized drug candidates and accelerate them through clinical development and regulatory approval.

By way of our innovative business model, we are rapidly expanding our pipeline and family of business units. Since our inception just two years ago, we have launched several subsidiary companies, including Axovant Sciences<http://axovant.com/> (Alzheimer’s disease and other dementias) in a record-setting IPO, Myovant Sciences<http://myovant.com/> (women’s health and prostate cancer), Enzyvant Sciences<http://www.enzyvant.com/> (Farber disease), among others.



If you have any questions, please contact us at campusrecruiting at roivant.com<mailto:campusrecruiting at roivant.com> or at (646) 677-4688. We look forward to seeing you there!


Sincerely,
Joyce Hong ’16
Austin Gromatzky ‘15

-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://mailman.mit.edu/pipermail/bioundgrd/attachments/20160929/07420a37/attachment-0001.html
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 12853 bytes
Desc: image001.png
Url : http://mailman.mit.edu/pipermail/bioundgrd/attachments/20160929/07420a37/attachment-0001.png